Evidence map›Paper›PMID 38024612›Full record

ReviewEJHaem2023

Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma.

Keri Toner, Carl E Allen, Shweta Jain, Brad Kahl, John Leonard, Heather Wasserstrom, Jonathan W Friedberg, Nita L Seibel, Kara Kelly

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EJHaem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Keri TonerCenter for Cancer and Blood Disorders Children's National Hospital Washington District of Columbia USA.ORCID https://orcid.org/0000-0002-9324-7314
Carl E AllenBaylor College of Medicine Texas Children's Hospital Houston Texas USA.
Shweta JainClinical Development Seagen Inc. Bothell Washington USA.
Brad KahlDepartment of Medicine Division of Oncology Washington University in St. Louis School of Medicine St. Louis Missouri USA.
John LeonardWeill Department of Medicine Division of Hematology and Medical Oncology Weill Cornell Medicine New York New York USA.
Heather WasserstromClinical Development Team Pediatrics Hematology and Cellular Therapy at Bristol Myers Squibb New York New York USA.
Jonathan W FriedbergWilmot Cancer Institute University of Rochester Rochester New York USA.
Nita L SeibelDivision of Cancer Treatment and Diagnosis National Cancer Institute National Institutes of Health Bethesda Maryland USA.
Kara KellyRoswell Park Comprehensive Cancer Center University at Buffalo Jacobs School of Medicine and Biomedical Sciences Buffalo New York USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphoma is one of the most common cancers in adolescents and young adults, but historically, this population has had lower clinical trial enrollment and improvements in overall survival as compared to other age populations. There are multiple challenges that are unique to this population that have affected drug development and clinical trial enrollment. Our panel of experts have identified barriers, and in this review, we discuss current methods to address these barriers as well as potential solutions moving forward.

Indexed as

adolescent and young adultsclinical trialslymphomasnew drug development

Identifiers

PMID38024612
PMCPMC10660108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.